This page shows the latest Waylivra news and features for those working in and with pharma, biotech and healthcare.
Waylivra (volanesorsen) is an antisense drugs, used for the treatment of a rare inherited disorder called familial chylomicronemia syndrome (FCS). ... Waylivra was Akcea’s second drug to reach the market last year after transthyretin-related
roll-out stage for two new products, Tegsedi (inotersen) for hereditary transthyretin-mediated amyloidosis and Waylivra (volanesorsen) for familial chylomicronemia syndrome (FCS).
EU becomes the first market for the new drug. Akcea has been granted a conditional approval for Waylivra, its antisense drug for rare inherited disorder familial chylomicronemia syndrome (FCS), in Europe. ... Waylivra last August despite a 12 to 8 vote
NICE’s ruling adds to the good news for Akcea, which in March gained a CHMP recommendation for Waylivra (volanesorsen), which would be its second drug to reach market.
Akcea's FDA-rejected Waylivra also recommended. The EMA’s main advisory committee for medicines backed new indications for AstraZeneca and Merck &Co/MSD’s Lynparza and Sanofi’s Dupixent that ... The committee recommended a conditional marketing
FDA rejects Waylivra, Roivant group continues gene therapy drive, UK biotech gains £637k. ... The regulator's Division of Metabolism and Endocrinology Products issued the response to Waylivra (volanesorsen), Akcea's treatment for the ultra-rare and
More from news
Approximately 2 fully matching, plus 5 partially matching documents found.
WE’RE ON A MISSION
To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....